CCAAT enhancer-binding protein beta (C/EBPb) is a pioneer transcription factor that specifies cell differentiation. C/EBPb is intrinsically unstructured, a molecular feature common to many proteins involved in signal processing and epigenetics. The structure of C/EBPb differs depending on alternative translation initiation and multiple post-translational modifications (PTM). Mutation of distinct PTM sites in C/EBPb alters protein interactions and cell differentiation, suggesting that a C/EBPb PTM indexing code determines epigenetic outcomes. Herein, we systematically explored the interactome of C/EBPb using an array technique based on spot-synthesized C/EBPb-derived linear tiling peptides with and without PTM, combined with mass spectrometric proteomic analysis of protein interactions. We identified interaction footprints of $1,300 proteins in nuclear extracts, many with chromatin modifying, chromatin remodeling, and RNA processing functions. The results suggest that C/EBPb acts as a multi-tasking molecular switchboard, integrating signal-dependent modifications and structural plasticity to orchestrate interactions with numerous protein complexes directing cell fate and function.
INTRODUCTION
CCAAT enhancer-binding proteins (C/EBPa, b, d, 3) are basic leucine zipper (bZip) transcription factors that regulate chromatin structure and gene expression by dimerization and binding to cis-regulatory, palindromic 5 0 ATTGC$GCAAT3 0 , or quasi-palindromic DNA sites in gene enhancers and promoters. Prototypic C/EBPb is widely expressed, highly regulated at the post-transcriptional level, and integrated in many signaling events communicating extracellular cues to epigenetic changes, examples of which include adipogenesis, hematopoiesis, innate immunity, female fertility, skin function, apoptosis, and cellular senescence (Nerlov, 2008; Rodier and Campisi, 2011; Tsukada et al., 2011) .
In early hematopoiesis and adipogenesis, C/EBPb acts as a pioneering factor that orchestrates complex steps in cell fate commitment (Kajimura et al., 2009; Lichtinger et al., 2012; Muller et al., 1995; Ness et al., 1993; Siersbaek et al., 2011) . C/EBPb communicates with numerous other transcription factors, co-factors, histone modifiers, and chromatin remodeling complexes to alter the susceptibility of chromatin to the gene regulatory machinery. C/EBPb induces lymphoid-myeloid trans-differentiation and accelerates acquisition of the induced pluripotent state by the Yamanaka set of reprogramming transcription factors (Di Stefano et al., 2016; Kowenz-Leutz and Leutz, 1999; Stoilova et al., 2013; Xie et al., 2004) . The chromatin and gene regulatory functionality of C/EBPb is linked to distinct regions and post-translational modifications (PTMs) that suspend auto-inhibition, direct the activity of C/EBPb, and regulate recruitment of chromatin remodelers and writers of histone modifications (Kowenz- Leutz and Leutz, 1999; Kowenz-Leutz et al., 1994 Lee et al., 2010b; Mo et al., 2004; Pless et al., 2008; Siersbaek et al., 2011) . C/EBPb functions are controlled by extracellular signaling cascades involving receptor tyrosine kinases, cytokine receptors, Ras GTPases, mitogen-activated protein kinases, and cyclic AMP and SMAD signaling, and by more complex conditions such as metabolic adaptation, inflammation, senescence, or stress responses (Nerlov, 2008; Rodier and Campisi, 2011; Tsukada et al., 2011) . The complexity and diversity of C/EBPb activities in various cell lineages raises the question of how a single transcription factor can participate in a multitude of regulatory events. Previous research suggested that the combinatorial outcome of post-transcriptional modifications and PTMs in conjunction with intrinsic structural plasticity enables the C/EBPb protein to adopt a plethora of context-and signal-dependent states that facilitate a variety of interactions Nerlov, 2008; Tsukada et al., 2011) .
Post-transcriptional regulation of C/EBPb generates three isoforms (LAP*, LAP, and LIP) by alternative translation initiation of the single-exon C/EBPb transcript. As consecutive C/EBPb start sites are positioned in the same reading frame, the isoforms vary in their gene regulatory N-terminal extensions but retain the same C-terminal dimerization and DNA-binding bZip domain (Wethmar et al., 2010) . The diversity of C/EBPb isoforms is further increased by numerous PTMs of amino acid side chains; in addition to phosphorylation of serine, threonine, and tyrosine residues, lysine acetylation and methylation also occurs, as does methylation of arginine. Enzymes responsible for PTM of C/EBPb include CARM1/PRMT4, G9A/EHMT2, and CREBBP/KAT3A, all of which also serve as epigenetic histone code writers. The decoration of C/EBPb by PTM alters its capacity to engage in protein-protein interactions (PPI) and to direct cell fate, suggesting that the signal-dependent C/EBPb modification index reflects integration of various upstream signaling events to adjust its interactome and to determine its gene regulatory and epigenetic capacity . The combination of translational modifications and PTMs may thus encrypt the dynamic interactome, with C/EBPb being the keystone for a wide range of functional outcomes (Lee et al., 2010b; Sebastian et al., 2005; Sterneck et al., 1997; Stoilova et al., 2013) .
The C-terminal third of C/EBPa, b, d, 3 contains highly conserved DNA-binding and bZip domains that may dimerize within an extended trans-regulatory bZip network including C/EBP, AP-1, and ATF transcription factors. The N-terminal two-thirds region of the C/EBP primary structure is predicted as an intrinsically disordered region (IDR) (Miller, 2006) . Phylogenetic analysis, nevertheless, suggests that the C/EBP N terminus also contains several highly conserved short peptide regions (CRs) that are enriched in amino acids with hydrophobic and bulky side chains. These CRs are discontinuous and separated by less conserved and family-specific regions of low complexity characterized by a predominance of small and polar amino acids Tsukada et al., 2011) . Experimental studies involving a large number of deletions and CR/IDR shuffling mutants suggested a highly modular, context-dependent functionality of N-terminal C/EBPb CRs (Kowenz- Leutz et al., 1994; Lee et al., 2010b; Leutz et al., 2011; Williams et al., 1995) . Screening for interaction partners using N-terminally derived C/EBPb peptides further supports the notion that many C/EBPb interactions may occur in a modular and dynamic fashion that relies on molecular recognition features (MoRFs) and short linear peptide motifs (SLiMs) in combination with adjacent PTMs (Dunker et al., 1998; Leutz et al., 2011; Tompa et al., 2014; van der Lee et al., 2014; Wright and Dyson, 1999) .
Based on previous observations of the modular structure and biological functionality of C/EBPb peptide regions, we developed a novel technique to systematically explore the C/EBPb interactome. Briefly, C/EBPb was deconstructed into small linear peptides of 14 amino acids immobilized on a solid-phase matrix. The starting point for each peptide was shifted by four amino acids, creating a tiled peptide array covering the entire amino acid sequence of C/EBPb. PTM-containing peptides were included according to recorded modifications and their position in the primary C/EBPb structure. The matrix was incubated with nuclear extracts, and protein enrichment on individual peptide spots was identified and quantified by mass spectrometry. The assay, termed protein interaction screen on peptide matrices (PRISMA), revealed hundreds of C/EBPb-and PTM-specific protein interactions that left footprints on C/EBPb-derived peptides. Based on comparison with other affinity enrichment approaches, 45 protein complexes were predicted and several novel interactions with proteins and complexes were experimentally confirmed. as schematically depicted in Figure 1B and detailed in Table S2 . To cover all linear binding regions of the entire CEBPb protein sequence, tiling peptides 14 amino acids long with an offset of mostly four amino acids were spot synthesized on a cellulose acetate matrix using Fmoc synthesis. As PTMs were previously shown to affect CEBPb protein interactions and functionality, PTM peptides with S/T/Y-phosphorylation; K-acetylation; K-, R-methylation; and R-citrullination were included in the screen matrix. In total, the solid matrix contained 203 immobilized peptides, covering known and potential post-translational side chain modifications.
The C/EBPb PRISMA Screen
To examine the linear CEBPb interactome, two replicates of the peptide matrix were incubated with nuclear extracts of HeLa cells. HeLa cells express CEBPb, and commercially available nuclear extracts have been used successfully by many research groups for the purification of biologically active proteins and protein complexes involved in gene regulation ( Figure 1B ). Individual peptide spots were excised and bound proteins proteolytically digested and analyzed by high-resolution mass spectrometry. In total, 406 analytical mass spectrometric 1-h runs were performed (approximately 17 days of measurement), and spectra were interpreted automatically using the MaxQuant software package.
Enrichment efficiency by PRISMA was examined by comparing the PRISMA intensity distribution with the total proteome of the nuclear extract. Approximately 5,100 proteins were identified and quantified in the nuclear cell extract using the intensity-based absolute quantification method (Schwanhausser et al., 2011) . The copy number of proteins in the nuclear cell extract and the number of proteins bound in the PRISMA screen spans six orders of magnitude, suggesting that the identified binders are not biased toward highly abundant proteins (Smits et al., 2013 ; Figure S1 ). Furthermore, the distribution of peptide or protein interactions was not attributed to physicochemical parameters of the peptides, as evidenced by comparison of the accumulated interaction intensities with peptide hydrophobicity (gravy index) and isoelectric points, which were determined for all non-modified PRISMA peptides. These results suggest that the PRISMA peptides on the matrix retained their specific protein-binding properties.
Data Processing of C/EBPb Peptide-Binding Proteins
An initial inspection of the two replicate datasets revealed signal intensity variation of the interacting proteins. The two datasets were therefore integrated to increase robustness, as outlined in Figure 1C and as explained in the Methods. The main source of variation arose from proteins that were identified only once on different peptide spots. This led to single (low confidence) and double (high confidence) identification categories for each peptide. The signal intensity for each protein was then normalized between 0 and 1 across all 203 matrix peptides. Individual peptides displayed large differences in binding partner profiles, further indicating the specificity of the interactions, because random binding would be expected to result in a more equal distribution of interacting proteins. Further analysis of the data showed that $25% of the identified proteins bound to multiple C/EBPb peptides across the array with low but varying intensity. Although these proteins may promiscuously bind to many distant peptides, some sections of the array showed much higher signals. To minimize noise from background binding, signal intensities for each (E) Number of proteins in the two PRISMA datasets that show consecutive peptide binding (core interactions, dark amber).
(F) Overlap of three affinity-purification-based datasets of C/EBPb interactors as described in the literature and combined with data obtained from a proteomic interaction screen in SU-DHL1 cells. Overlaps were determined using immunoprecitation (IP) SU-DHL1 as reference dataset and thus the numbers add up to the size of this set only (see Methods).
(G) Overlap of the PRISMA-derived C/EBPb interactor datasets from (E) (union of SET1 and SET2, light amber) with core interactions (dark amber) from the union of the three datasets from (F) (blue). Overlaps are given using the PRISMAderived data as reference datasets. The overlap count using the union of the datasets from (F) as a reference dataset is denoted in brackets. protein were filtered for binding above 90% of the protein's signal distribution (outlier filtering), removing all signals below this threshold. Another filtering criterion for discriminating the most robust interactors was based on the consecutive binding behavior of tiling peptides of the C/EBPb primary structure.
The rational here is that by shifting the sequence of tiling peptides by four amino acids, some of the SLiMs and fractions thereof are included in more than one peptide. This may generate maximal binding signals for peptides containing optimal SLiM and adjacent supporting amino acids, and attenuated signals from neighboring peptides in which the particular SLiM is shifted or only partially included. We used this predicted binding behavior to stringently filter the dataset further to remove all proteins that failed the consecutive binding criterion ( Figures 1D and 1E ; see also Methods). In total, 2,363 interacting proteins were identified (Table S3) , of which 1,384 proteins were detected in both replicates and 1,302 proteins fulfilled the consecutive binding criterion and were defined as C/EBPb core interactions (bCI; Figure 1E ).
Validation of the PRISMA-Derived Dataset
To assess the biological significance of data derived by PRISMA, we compared PRISMA data (SET1, SET2, bCI) to previously identified C/EBPb interactome data, as shown in Figure 1F (Siersbaek et al., 2011; Steinberg et al., 2012) . In addition, we performed pull-down experiments using C/EBPb antibodies and SU-DHL1 cells that express a high amount of CEBPb and analyzed the CEBPb interactome by mass spectrometry (Table S4 ). In total, 1,369 proteins were significantly enriched in SU-DHL1 C/EBPb samples compared with control samples using a false discovery rate (FDR) cutoff of 5%. The list of SU-DHL1 C/EBPb interactors was included to extend the existing CEBPb interaction datasets. The PRISMA core interaction data covered between 38% and 59% of the affinity-purification-based datasets (see Supplemental Information). Affinity purification-based datasets were then combined, and the overlap with PRISMA data was determined on the basis of their UniProt identifier entries, as shown in Figure 1G (see Methods). In total, 47% of data in all three sets were also found in the PRISMA core interactions, and 64% of PRISMA core interactions were also found in at least one of the other datasets. To estimate the FDR of the C/EBPb interactor data detected by PRISMA, we employed the method proposed previously (D'Haeseleer and Church, 2004) , which relies on comparing the intersections of protein interaction datasets to approximate the number of false-positive PPIs. We obtained FDRs of 11.2% and 13.9% for proteins detected in PRISMA replicates 1 and 2, respectively (SET1 and SET2 in Figures 1D and 1E ; see Supplemental Information for details). FDRs were reduced to values below 4% when applying the filtering step leading to PRISMA core interactions. These results suggest that PRISMA data depict strong overlap and extensive coverage of the interactome related to native C/EBPb. We conclude that the PRISMA method successfully extends the interactome data and serves as a resource for locating interaction footprints on C/EBPs.
High-Resolution C/EBPb Interactome Footprints
The global protein interaction profile obtained from the C/EBPb peptide matrix is depicted as a nonhierarchically clustered heatmap in Figure 2A . The numerical distribution of proteins identified by individual peptides is shown in the upper part of Figure 2A . Peptides representing the DNA-binding region (DB) and the C-terminal part of the leucine zipper (LZ) exhibit the highest number of protein interactions, yet locally enriched binding hotspots were also found with peptides from the N-terminal part of C/EBPb.
Clusters of protein-peptide interactions tended to co-localize with regions predicted to undergo disorderto-order transition during interaction with binding partners and coincide with the profile of conserved C/EBPb regions (CR1À7), interaction and MoRF predictions (Disfani et al., 2012; Meszaros et al., 2009) , as shown in Figure 2B . Predicted IDRs in the transactivating domain (CR1À4), IDR2 (between CR2 and CR3), and regulatory domain between CR7 and the basic or acidic region (IDR7) also displayed large numbers of interaction partners. Next, PRISMA-derived data were compared with previously mapped C/EBPb-interacting proteins. As shown in Figure 2C , both co-activator acetyltransferases, CBP and P300 (KAT3A/KAT3B), generated highly similar interaction footprints in the transactivation regions CR4 (strongest binding) and CR3 (additional binding), with some residual binding in CR2. Both C/EBPb and C/EBPd have been shown to interact with CBP/p300, and the main interaction region encompasses the CBP Taz2 domain as well as CR3 and CR4 in both C/EBPs. Removal of CR3 or CR4, or mutation of a critical tyrosine residue in CR3 or the DLF motif in CR4 all abrogated interaction with Taz2 and subsequent transcriptional co-activation (Kovacs et al., 2003; Schwartz et al., 2003) . Previously published crystallographic data revealed that CR3/CR4 regions in C/EBP 3 may adopt an L-shaped a-helical structure that folds into the p300 Taz2 domain (Bhaumik et al., 2014) , in agreement with the CBP/P300 protein footprints revealed by PRISMA ( Figure 2C ).
The multi-subunit Mediator (MED) complex (Conaway and Conaway, 2013; Jeronimo and Robert, 2017) has also been reported to interact with C/EBPb (Mo et al., 2004) , and several MED components were identified in a previously published C/EBPb interaction dataset (Siersbaek et al., 2014) , as well as in the SU-DHL1 interactome presented here. As shown in Figure 2C , PRISMA revealed 20 components of the multi-subunit MED complex that predominantly interact with CR2-, CR3-, and CR4-derived peptides from C/EBPb TAD.
CR1 of the LAP* C/EBPb isoform was reported to specify conjugation by SUMO3 (Eaton and Sealy, 2003) and in accordance, PRISMA showed interaction between SUMO3 and CR1. CR1 also interacts with the Brg1/SMARCA4 ATPase of the SWI/SNF/BAF complex. Moreover, the Brg1-CR1 interaction is sensitive to methylation of arginine 3 (Kowenz- Leutz et al., 2010) . Consistent with these results, PRISMA revealed interaction of Brg1 with the unmodified CR1 peptide, but not with the methylated peptide. Moreover, interactions with 10 additional protein components of BAF-SWI/SNF-type protein complexes were detected with various peptides of the C/EBPb transactivation domain and the bZip domain, indicating multiple interactions between C/EBPb and chromatin modifying complexes, as previously suggested (Kowenz- Leutz and Leutz, 1999) . Discrete parts of the C/EBPb primary structure have previously been assigned to different biochemical or cellular functions. Protein binding data from different C/EBPb regions were extracted and GO term analysis performed for each of the regions to map structure-function relationships, as shown in Figure S2B . Some functional attributions displayed partition over several regions of C/EBPb (regulation of gene expression, RNA splicing), whereas others are more localized to distinct regions. For example, basic regions and DB show strong enrichment for ''regulation of mitotic cell cycle processes'' or ''nuclear export,'' whereas ''nuclear import'' is associated with CR5, CR7, IR7, and LZ. The C-terminal region of C/EBPb is involved in the majority of GO terms, whereas transcription factor co-activator functions are mainly associated with N-terminal activation of CR2, CR3, CR4, and IR7.
Enrichment

C/EBPb-Interacting Protein Complexes
Next, PRISMA data were analyzed for potential enrichment of large protein complexes interacting with CEBPb. In addition to anticipated C/EBPb-interacting complexes such as the basic RNA polymerase II (RNAPII) transcription machinery or MED, previously unknown interrelations became apparent. These included potential complexes involved in the RNA transcript processing machinery responsible for transcript capping, splicing, termination, and polyadenylation. Interactions included 3'-end processing, cleavage, and polyadenylating factor (CPSF1, 3, 7, 30, and 100), and several components of the and 10). Furthermore, many components of the nuclear pore and associated adapter complexes were identified. In addition, components of the transcript export THO-TREX complex, including THO1, 2, 3, 5, 6, 7, Aly, DDX39, and the THO-TREX-associated mRNA export factors Nxf1-Nxt1 were identified, along with a large number of heterogeneous nuclear ribonucleoproteins that may couple transcript splicing, maturation, and the formation of messenger ribonucleoprotein particles. Taken together, these data imply the existence of a previously unknown connection between CEBPb and several steps involved in transcript generation, processing, maturation, and transport (Muller-McNicoll and Neugebauer, 2013; Wickramasinghe and Laskey, 2015) .
Proteins co-occurring in both the PRISMA and SU-DHL1 proteomic data were then systematically explored to identify soluble protein complexes listed in the CORUM database (March 6, 2017) using the g:Profiler bioinformatics toolkit (Reimand et al., 2016; Ruepp et al., 2010) . A list of 1,432 human protein complexes built from 2,678 proteins (single UniProt identifier; ID) was derived after removal of redundant and nonhuman complex entries. Proteins listed in PRISMA replicates (SET1 + SET2) and protein interactions derived from SU-DHL1 IP-mass spectrometry data were matched by UniProt and gene name ID using Perseus version 1. 5.2.4 (Tyanova et al., 2016) . Redundant gene names and isoform entries were merged into a single UniProt ID for each protein. Altogether, 816 proteins of the PRISMA-derived dataset and 490 proteins of the IP SU-DHL1 dataset were included in any of the 1,432 CORUM complexes. The 1,432 CORUM complexes were then ranked by a combination of two criteria: (1) the percentage of proteins in complexes obtained by PRISMA and (2) deviation from randomness of the coverage of the complexes obtained by PRISMA and SU-DHL1 (p values with CORUM background, see Supplemental Information for details). Considering only complexes sharing at least one protein with the PRISMA dataset and which have at least three overlaps with PRISMA and SU-DHL1 data resulted in a ranked list of 417 candidate complexes (see Figure S3 and Table S5 ). Whenever possible, complexes were grouped into categories indicating functional connections, such as DNA repair, nuclear pore, or centromere, in addition to well-characterized multi-subunit complexes, such as MED, SWI/SNF, MLL, nucleosome remodeling deacetylase (NuRD), and others. As shown in Figure 3A , 45 multi-protein complexes and categories were extracted, and normalized protein interaction values at any of the 203 C/EBPb peptides were summed over all instances of the category in the list and depicted as a bar plot to visualize the distribution of interaction sites of different categories or complexes in relation to the C/EBPb primary structure. These 45 entities were composed of 30 complexes or categories representing the full upper quartile of the ranked complex list (i.e., up to rank 104, Table S5 , with minor exceptions, Figure S3 ), together with 15 lower-ranking functional counterparts. Figure 3B shows prominent node-link diagrams of a selection of 14 multi-protein complexes among the highest ranking categories that share many proteins identified by both PRISMA and SU-DHL1 immunoprecipitation methods.
Validation of Region-and PTM-Specific C/EBPb Interactions
Next, conventional protein pull-down, immunoprecipitation, and immunoblotting analysis were used in combination with CEBPb mutants to validate data from the PRISMA-derived interactome (Figure 4 ). According to PRISMA, the nuclear factor kappa B subunit RelA, the signal transducer and activator of transcription STAT3, and the nuclear pore complex protein NUP50/NPAP60L predominantly interacted with peptides located in CR7. Bacterially expressed GST-C/EBPb constructs were probed with HEK293 extracts to examine RelA and NUP50/NPAP60L interactions. As shown in Figures 4B and 4D (lower panels) affinity capture with GST-CEBPb constructs or co-immunoprecipitation of STAT3 with the C/EBPb mutant protein lacking CR7 and subsequent immunoblotting confirmed CR7 as the interaction site for all three proteins. to CR3 and CR4, respectively, and minor binding elsewhere in C/EBPb. Various C-terminally FLAG-tagged C/EBPb mutant constructs lacking CR1, CR2 (5D43), the entire TAD (5D141), CR4 (LAP*D4), CR7 (LAP*D7), or both CR4 and CR7 (LAP*D4,7) were expressed in HEK293 cells to examine selective and multi-site interaction with resident DMAP1/GCN5 or their respective complexes. As shown in Figures 4C and 4D , pull-down and immunoblotting revealed that removal of the DMAP1 minor binding site in CR2 partially abrogated the interaction and removal of binding to CR3 completely abrogated the interaction. Similarly, removal of the binding site for GCN5 located in CR4 strongly affected GCN5 association and deletion of the binding site in CR7 entirely abolished binding to C/EBPb.
The Impact of PTMs on C/EBPb-Mediated Interactions
Detection of PTM-dependent protein interactions in linear C/EBPb peptides was a major objective for the development of the PRISMA screening method. Protein binding to each PRISMA peptide and its PTMmodified versions were therefore examined. The binding signal for each protein was normalized against the signal from the corresponding unmodified peptide to compare enhanced or reduced binding. Interacting proteins were then clustered, as shown in Figure S4 . Depending on PTM, as exemplified in Figure 5A , interactions fell into the following four categories: (1) generally repressed binding, (2) PTM-independent binding, (3) PTM-specific binding, and (4) generally enhanced binding. Most of the identified binding partners were indifferent to the type of PTM and were classified as binding proteins that may recognize parts of the peptide sequences. Generally enhanced binding may in part relate to the fact that many PTMs increase hydrophobicity and may thus enhance interactions non-specifically. The most interesting binding partners are expected to be found in the last two categories and represent proteins that are disturbed by any PTM in the peptide or represent interaction partners that were attracted or repelled by a particular PTM. Examples of the latter are the NuA4/TIP60 complex components DMAP1 and YEATS4, both binding to CR3, or RelA and the transducin-like enhancer protein TLE3 binding to CR7, which depends on the methylation status of arginine residues that were subsequently examined.
The transactivation region CR3 (residues 53-68: AIGEHERAIDFSPYLE) contains an arginine residue that is conserved in C/EBPb, but not in C/EBPa,d, 3, and was previously found to be methylated . The PRISMA data suggested that DMAP1 and YEATS4 binding to CR3 depended on methylation of R59. Another interaction hotspot was mapped to the start site of the highly conserved, alternatively initiated LIP C/EBPb isoform that also represents part of the regulatory region CR7 (residues 158-170: FPFALRAYLGYQAT). The respective arginine residues in both chicken (R60, R193) and rat (R58, R162) were previously found to be methylated. Mutation of the equivalent amino acid residue to alanine or leucine in chicken C/EBPb strongly altered transcriptional activity, suggesting that the methylation status of the conserved arginine in CR7 may be critical . Wild-type (WT) C/EBPb, methylation-defective R60A and R193A, and methylation-mimicking R60L and R193L constructs were subjected to co-immunoprecipitation to compare alterations in binding, as shown in Figure 5B . As suggested by PRISMA, interaction of all four proteins with C/EBPb was sensitive to the amino acid side chain configuration at the respective arginine positions, demonstrating both amino acid and PTM specificities, in addition to evolutionary conservation of chicken and rat C/EBPb interactions. Binding of YEATS4 or DMAP1 to C/EBPb was enhanced or tolerated by the R60L exchange, but not the R60A exchange, respectively, confirming the side chain specificity and preference for increased side chain hydrophobicity. RelA binding to the R193A mutant was slightly enhanced when compared with WT or reduced by the R193L mutant, respectively, confirming avoidance of the methylated, more hydrophobic PRISMA peptide. By contrast, the TLE3 co-repressor (Agarwal et al., 2015) favored binding to the R193L mutant, suggesting that the increase in hydrophobicity by methylation of the arginine side chain, but not the positive charge, was important for interaction with TLE3. Pull down of TLE3 by immunoprecipitation confirmed preferential binding of C/EBPbR193L, as shown in Figure 5C . Next, we performed methylation assays with the protein arginine methyltransferase PRMT4/CARM1 and C/EBPb peptides, as shown in Figure 5D . C/EBPbR193 was identified as a methylation target in CR7, in addition to the previously described R3 in CR1 (Kowenz- Leutz et al., 2010) . Co-immunoprecipitation of TLE3 together with WT C/EBPb was dependent on co-expression of PRMT4/CARM1 ( Figure 5E ). Importantly, and irrespective of co-expressed Both C/EBPb and TLE3 had been described as important regulators in adipogenesis . As shown in Figure 5F , ectopic expression of C/EBPb in 3-isobutyl-1-methylxanthine (3T3L1) cells induced partial adipogenic differentiation in the absence of the in vitro differentiation cocktail (IBMX, insulin, dexamethasone). Fat cell differentiation was evident by up-regulation of the adipogenic genes ADIPOQ, CFD, and FABP4 ( Figure 5F , bar graph panel) and enhanced oil red O staining (below) in local adipogenic nests. Adipogenic gene expression of ADIPOQ and FABP4 was enhanced by the C/EBPbR193L mutant, and TLE3 cooperated with C/EBPb WT and more strongly with C/EBPbR193L, but not with the C/EBPbR193A mutant, to activate ADIPOQ, CFD, and FABP4. We conclude that PRISMA may uncover functional C/EBPb PTM-regulated protein-protein interactions to adjust the biology of C/EBPb.
Novel Connections between C/EBPb, Transcription Elongation, MLL, and NuRD
Of particular interest was the observation that many proteins forming part of the machinery involved in RNAPII pausing and elongation were included in the PRISMA data. Components of the Trithorax MLL/ Set1/COMPAS histone H3 lysine 4 (H3K4) methyltransferase complexes (Shilatifard, 2012) were also represented in the dataset, raising the possibility of a connection between C/EBPb, enhancer/promoter binding, and regulation of RNAPII processivity. Many components implicated in both processes were found, including the MLL complex components CHD3 and 4 (Mi-2), ASH2, Dpy30, PTIP, and HCF-1; the general transcriptional elongation factor B (TFIIS) and associated elongin A/B/C factors (Aso et al., 1995) ; the P-TEFb components cyclinK/T1, cdk9, and additional regulatory components including LARP7, HEXIM1, SPT5 (DSIF), and the chromatin adaptor bromodomain factor Brd4 and components of the super elongation complex (SEC), including AF9, PCAF1, and AF4 (AFF1) (Luo et al., 2012) . AFF1 is a central SEC scaffold component, and AF9 and ENL are highly similar YEATS domain family members that compete for binding to AFF1. The N-terminal YEATS domain of AF9 and ENL both bind to the PAF complex to connect SEC to RNAPII on chromatin templates. The CDK9/CYCT1 P-TEFb complex is required for rapid transcriptional induction, phosphorylation of the C-terminal domain of RNAPII, and engagement of BRD4, which also interacts with H3K9ac. P-TEFb is also associated with a 7SK snRNA subcomplex that contains the regulatory components LARP7, HEXIM1, and SPT5 (DSIF) and connects to PAFc in the dynamic transcription elongation machinery (He et al., 2011; Luo et al., 2012; Peterlin and Price, 2006) . In addition, the histone chaperone FACT complex facilitates passage of the transcription apparatus through chromatin and is thought to restore the chromatin structure and the epigenetic state during transcription, replication, and repair (Hammond et al., 2017; Hondele and Ladurner, 2013; Orphanides et al., 1998) .
Immunoprecipitation and immunoblotting were performed to validate several of these novel connections. As shown in Figure 6 , multiple MLL, FACT, and SEC components were all co-immunoprecipitated with C/EBPb, confirming the predictive capacity of PRISMA. It is also important to note that AFF1, AF9, and ENL are among the most frequent oncogenic fusion partners with the MLL gene product that transforms early hematopoietic progenitors and causes childhood leukemia by short-circuiting enhancer and promoter activation and transcriptional elongation checkpoint controls (Krivtsov and Armstrong, 2007; Shilatifard, 2012; Slany, 2009; Smith et al., 2011) .
The Mi2/NuRD corepressor complex is widely expressed and maintains chromatin in a closed state by ATPdependent chromatin remodeling and histone tail deacetylation. Some of the NuRD components (CHD3/ 4(Mi2), HDAC1, RBBP4/7, MTA1,2, GATAD2A/p66a, MBD2, MBD3) identified by PRISMA, SU-DHL1 IP, and other approaches (Steinberg et al., 2012; Siersbaek et al., 2014) are shared with the SIN3A and CoREST repression complexes (Gregoretti et al., 2004) , and all were implicated by CORUM analysis (Figures 3 and S3 , Table  S5 ). Two major NuRD complexes contain the unique methyl-CpG-binding proteins MBD3 or MBD2, of which the latter may also associate with the WDR77(MEP50)/PRMT5 sub-module (Le Guezennec et al., 2006; Zhang and Yinghua, 2011) . Immunoprecipitation of either MBD2 or MBD3 revealed association of C/EBPb, Mi2, and MTA with both MBD components, whereas only MBD2 co-precipitated with the WDR77(MEP50)/PRMT5 sub-module, suggesting that C/EBPb may associate with both types of NuRD complexes.
DISCUSSION
In conclusion, the PRISMA technique reveals a comprehensive and PTM-dependent interactome of the disordered C/EBPb transcription factor hub and permits the detection of footprints of protein interactions and protein complexes. The results presented in this article suggest that C/EBPb is involved at the nexus between enhancer and promoter regulation, in many aspects of pre-and post-transcriptional control, including initiation and pausing control, splicing and exosomal RNA degradation, polyadenylation, and RNA maturation, and in nuclear export. Previously, we described an array peptide screening system (APS) for PTM-dependent protein interactions that relied on fluorophore-based detection of peptide interactions with bacterially expressed human proteins immobilized on macroarrays. Although it is difficult to compare APS with PRISMA because of major differences in peptide choice, peptide length, biochemical conditions, local concentration of interaction partners, signal-to-noise ratio, or complexity of the protein expression library and requirement of a renaturation step, 35 common APS/PRISMA interaction partners, including Brg1/SMARCA4, were found with an N-terminal APS peptide and a comparable section covered in PRISMA that contained CR1 .
The high local concentration of peptides in matrix spots may limit free diffusion and overcome the dissociation problem of low-affinity interactions (Ruthenburg et al., 2007) . These features permit the detection of weak interactions and interactions with rare protein partners. The interaction screen developed herein is augmented by inclusion of amino acids with modified side chains to enable detection of PTM-dependent interactions on a global scale. Together, the interaction footprints and PTM-dependent data may help in the rational design of mutants to further explore the functional C/EBPb interactome and aid in the development of pharmacological inhibitors of protein interactions. The PRISMA workflow is applicable to other regulatory proteins and particularly to transcriptional regulators with a high degree of intrinsic disorder, such as Myc-or various Hox proteins. PRISMA may help to discern highly complex and dynamic transcription factor functions that arise through IDR-and PTM-regulated interactions.
PRISMA was developed for analysis of the interactome of proteins with a high degree of intrinsic disorder. Such proteins lack a defined 3D structure, and protein interactions and complex formation are based on SLiMs, PTMs, and intrinsic flexibility. IDRs in conjunction with PTMs may facilitate structural transitions in partner protein exchanges (Wright and Dyson, 2015) . Comprehension of the dynamics and context-dependent interactions between structurally flexible SLiMs and various partner proteins is an emerging hallmark of signal transmission and key to understand the regulation of chromatin structure and gene expression (Minde et al., 2017; Tompa et al., 2014; van der Lee et al., 2014; Wright and Dyson, 2015) . SLiM interactions often occur with high specificity but low affinity to enable multiple contacts of a dynamic nature, such as occurring during phase separation. Deciphering the functionality of SLiM/MoRF-type protein regions and PTMs in homeostasis and disease can be challenging when using full-length proteins due to functional redundancy and compensatory effects. A variant of PRISMA has meanwhile been employed to detect dysregulated interactions with disease-causing mutations occurring in IDRs (Meyer et al., 2018) . PRISMA data presented here thus provide a repository of high-molecular-resolution C/EBPb interactions and serve as a basis to explore gene regulatory and PTM-modulated C/EBPb functions.
Limitations of the Study
Protein interactions can be mediated by binding domains or by smaller interaction motifs. One key aspect of the study is the identification of the interactome of IDRs and SLiMs and binding regulation by PTMs. As the PRISMA technique is based on the use of peptides, the detection of interactions is limited to those that are based on structurally variable SLiMs, as binding directly depends on the amino acid sequence properties. The high local concentrations of the peptides on the membrane permit the detection of low-affinity interactors and leave components of their corresponding protein complexes intact under mild washing conditions. For interactions that are based on recognition of three-dimensional structures, however, the method will probably not be applicable. 
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Kme1
Kme2 Kme3 included variable modifications of methionine oxidation and N-terminal acetylation, deamidation (N and Q) and fixed modification of carbamidomethyl cysteine. The minimal peptide length was set to seven amino acids, and a maximum of two missed cleavages were allowed. The FDR was set to 0.01 for peptide and protein identifications. Unique and razor peptides with a minimum ratio count of 1 were considered for quantification. Retention times were recalibrated based on the built-in nonlinear time-rescaling algorithm. MS 2 identifications were transferred between runs with the 'Match between runs' option, in which the maximal retention time window was set to 0.7 min. Statistical analysis was performed using Perseus version 1.5.2.4. C/EBPβ pull-down and control samples were defined as groups and proteins and filtered by intensity value using a 'minimum value of 3 per group' as the threshold. After log2 transformation, missing values were imputed with random numbers from a normal distribution with a mean and standard deviation chosen to best simulate low abundance values below the noise level (width = 0.3; shift = 1.8). Significantly enriched proteins were determined using a volcano plot-based strategy, combining standard two-sample t-test p-values with ratio information. Significance corresponding to an FDR of 5% was determined by a permutationbased method (Tusher et al., 2001) . Equal sample load was confirmed by calculating the ratio of antibody intensities (mean log2 ratio = 0.1575).
Identification of C/EBPβ PTM sites by mass spectrometry
Eluates of anti-C/EBPβ pull-downs were ethanol precipitated and protein pellets were processed as described above for the interactome analyses. Peptides were analyzed on a Thermo Orbitrap Fusion instrument (Q-OT-qIT, Thermo). Sequential survey scans of peptide precursors covering different mass ranges (300-600, 550-850, 800-1100, 1050-1700 m/z) were performed at 120 K resolution with a 2×10 5 ion count target on the three most abundant precursor ions. Tandem MS was performed by isolation at 1.6 m/z with the quadrupole, HCD fragmentation with a normalized collision energy of 30, and rapid scan MS analysis in the ion trap. The MS 2 ion count target was set to 1×10 4 and the max injection time was 500 ms. Only precursors with a charge state of 2-7 were sampled for MS 2 . The dynamic exclusion duration was set to 60 s with a 10 ppm tolerance around the selected precursor and its isotopes. Data were analyzed by MaxQuant software version 1.5.1.2 as described above for interactome analysis with some modifications; the search included variable modifications of methionine oxidation and N-terminal acetylation, deamidation (N and Q), phosphorylation (S, T and Y), acetylation (K), methylation (K and R), dimethylation (K and R), trimethylation (K) and citrullination (R). Modification of carbamidomethyl cysteine was set as a fixed modification. The minimal peptide length was set to seven amino acids, and a maximum of four missed cleavages were allowed. The FDR was set to 0.01 for site identifications. To filter for confidently identified peptides, the MaxQuant score was set to a minimum of 40. Identified PTM sites were classified according to their localization probability (Class I >0.75, Class II >0.5, Class 3 >0.25).
In order to distinguish citrullination from deamidation, a modification resulting in a similar mass shift of the precursor, both modifications were included during MaxQuant data analyses as variable modifications, and at least one missed cleavage was required for citrullination site identification. When arginine and lysine are acetylated or methylated, trypsin often fails to cleave at that site, resulting in miss-cleaved peptides. Therefore, only the PTM sites, which were identified within the peptide, but not C-terminally localized, were considered as confidently identified.
Combining the two datasets and data filtering
The two datasets of the PRISMA measurement were analyzed in two batches due to restrictions of the MaxQuant software package. The two separate datasets were then integrated by calculating the average intensity value where two values were available, or by taking the single measured value if only one intensity measurement was available to prevent bias against single identifications. Single value intensities were annotated as lower confidence quantifications. Each of the data rows of the combined dataset, corresponding to intensity values of one protein over all 203 peptides, was first filtered according to the outlier criterion " = 0 " ≤ 90, where In is the intensity at peptide n, and P90 is the 90th percentile of the intensity value distribution of the protein, followed by normalization against the intensity of the highest value in each row using + , -./ 0 ( + 0 ) = " , where In is the intensity at peptide n. This was followed by an additional filtering step where all proteins were removed that did not show a consecutive binding pattern according to finding at least one intensity In with In > 0 and In+1 > 0 with In as the intensity at peptide n and only considering peptides without any PTM.
Construction of CORUM networks
For each complex identified in the CORUM database, the corresponding UniProt identifier was extracted and translated to an ensemblp identifier using the bioDBnet conversion tool (Mudunuri et al., 2009) . For each of the ensemblp identifiers, interactions were extracted from the STRING resource (Szklarczyk et al., 2015) . The interaction network was constructed using the igraph software package (Csardi G, 2006) and colored based on the source the of the interaction from the different datasets.
Relative binding to PTM-modified peptides
For each peptide and its PTM derivatives, the relative binding was calculated. For each protein and modified peptide, the intensity value of the unmodified form of the peptide was subtracted.
The resulting values were separated into five fractions and clustered according to their Euclidian distance.
Calculation of peptide properties
For calculation of peptide properties, the R peptides package was used, and properties were calculated and plotted using the ggplot2 packages (Wickham, 2009 ).
Use of the DAVID package
